Developer of cell therapy products designed to safely replace patients' diseased blood and immune system with a healthy
Drug Discovery📍 Menlo Park, CAFounded 2015
Current Valuation
$1.2B
as of 2020-Q2
UNICORN
Developer of cell therapy products designed to safely replace patients' diseased blood and immune system with a healthy one.
Company Profile
Founded
2015
HQ
Menlo Park, CA
Employees
336
Total Raised
$325M
Last Round
Series D — $192M (Jun 2020)
IPO Status
private
Fundraising Status
Series D · $192M · 6y 2mo ago
privateTotal raised $325M
Secondary Market
Implied price / share
$38
Last round price / share
$35.01
vs last round
+8.5%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$192M
Jun 2020
—
$1.2B
Health CareMedicalPharmaceutical
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2020-Q2. Refreshed quarterly.